Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03911102 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
A Phase 2 study, sponsored by Revance Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 63
- Enrollment target
NCT03911102 is a Phase 2 study that has completed, run by Revance Therapeutics. The registered enrollment target is 63 participants.
The verdict
NCT03911102, a Phase 2 study, has completed, sponsored by Revance Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 63 participants
- Enrollment target
Study Summary
A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
Interventions
- BIOLOGICAL DaxibotulinumtoxinA for injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2019-03-11 |
| Est. Completion | 2020-04-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03911102
The ClinicalTrials.gov registry entry for NCT03911102 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Revance Therapeutics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DaxibotulinumtoxinA for injection is the first listed.
NCT03911102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03911102 about?
NCT03911102 is a clinical study titled "Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines". A Phase 2a, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Treatment of Moderate or Severe Lateral Canthal Lines (LCL).
What is the current status of trial NCT03911102?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 63 participants. The study started on 2019-03-11. Estimated completion is 2020-04-23.
What interventions are being tested in trial NCT03911102?
The interventions under investigation include: DaxibotulinumtoxinA for injection (BIOLOGICAL).
Who is sponsoring clinical trial NCT03911102?
This trial is sponsored by Revance Therapeutics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.